vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and SOUTHERN FIRST BANCSHARES INC (SFST). Click either name above to swap in a different company.

SOUTHERN FIRST BANCSHARES INC is the larger business by last-quarter revenue ($31.8M vs $20.6M, roughly 1.5× Pulmonx Corp). On growth, SOUTHERN FIRST BANCSHARES INC posted the faster year-over-year revenue change (26.1% vs -8.7%). Over the past eight quarters, SOUTHERN FIRST BANCSHARES INC's revenue compounded faster (22.2% CAGR vs -0.5%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

First Community Bankshares, Inc. is a $2.43 billion bank holding company and the parent company of First Community Bank of Bluefield, Virginia, in the United States. As of 2012 First Community Bank had 45 locations in Virginia, West Virginia, and North Carolina, and two locations operating as Peoples Community Bank in Tennessee. As of April 21, 2023, First Community had $3.6 billion in assets.

LUNG vs SFST — Head-to-Head

Bigger by revenue
SFST
SFST
1.5× larger
SFST
$31.8M
$20.6M
LUNG
Growing faster (revenue YoY)
SFST
SFST
+34.8% gap
SFST
26.1%
-8.7%
LUNG
Faster 2-yr revenue CAGR
SFST
SFST
Annualised
SFST
22.2%
-0.5%
LUNG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LUNG
LUNG
SFST
SFST
Revenue
$20.6M
$31.8M
Net Profit
$-13.7M
Gross Margin
77.9%
Operating Margin
-40.9%
40.1%
Net Margin
-66.3%
Revenue YoY
-8.7%
26.1%
Net Profit YoY
5.5%
EPS (diluted)
$-0.33
$1.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
SFST
SFST
Q1 26
$20.6M
Q4 25
$22.6M
$31.8M
Q3 25
$21.5M
$31.1M
Q2 25
$23.9M
$28.6M
Q1 25
$22.5M
$26.5M
Q4 24
$23.8M
$25.2M
Q3 24
$20.4M
$23.8M
Q2 24
$20.8M
$23.1M
Net Profit
LUNG
LUNG
SFST
SFST
Q1 26
$-13.7M
Q4 25
$-10.4M
Q3 25
$-14.0M
$8.7M
Q2 25
$-15.2M
$6.6M
Q1 25
$-14.4M
$5.3M
Q4 24
$-13.2M
Q3 24
$-14.1M
$4.4M
Q2 24
$-15.3M
$3.0M
Gross Margin
LUNG
LUNG
SFST
SFST
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
LUNG
LUNG
SFST
SFST
Q1 26
-40.9%
Q4 25
-43.8%
40.1%
Q3 25
-66.9%
36.4%
Q2 25
-62.0%
30.0%
Q1 25
-64.6%
26.1%
Q4 24
-56.5%
27.3%
Q3 24
-69.3%
24.1%
Q2 24
-75.2%
17.0%
Net Margin
LUNG
LUNG
SFST
SFST
Q1 26
-66.3%
Q4 25
-46.1%
Q3 25
-64.9%
27.8%
Q2 25
-63.6%
23.0%
Q1 25
-64.1%
19.9%
Q4 24
-55.4%
Q3 24
-69.4%
18.4%
Q2 24
-73.7%
13.0%
EPS (diluted)
LUNG
LUNG
SFST
SFST
Q1 26
$-0.33
Q4 25
$-0.25
$1.19
Q3 25
$-0.34
$1.07
Q2 25
$-0.38
$0.81
Q1 25
$-0.36
$0.65
Q4 24
$-0.33
$0.69
Q3 24
$-0.36
$0.54
Q2 24
$-0.39
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
SFST
SFST
Cash + ST InvestmentsLiquidity on hand
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$45.8M
$368.7M
Total Assets
$120.0M
$4.4B
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
SFST
SFST
Q1 26
$61.6M
Q4 25
$69.8M
Q3 25
$76.5M
Q2 25
$75.5M
Q1 25
$74.6M
Q4 24
$70.9M
Q3 24
$63.3M
Q2 24
$63.5M
Total Debt
LUNG
LUNG
SFST
SFST
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
LUNG
LUNG
SFST
SFST
Q1 26
$45.8M
Q4 25
$54.1M
$368.7M
Q3 25
$60.0M
$356.3M
Q2 25
$69.1M
$345.5M
Q1 25
$77.7M
$337.6M
Q4 24
$85.8M
$330.4M
Q3 24
$93.9M
$326.5M
Q2 24
$101.2M
$318.7M
Total Assets
LUNG
LUNG
SFST
SFST
Q1 26
$120.0M
Q4 25
$129.3M
$4.4B
Q3 25
$138.3M
$4.4B
Q2 25
$147.2M
$4.3B
Q1 25
$150.7M
$4.3B
Q4 24
$162.8M
$4.1B
Q3 24
$167.4M
$4.2B
Q2 24
$172.6M
$4.1B
Debt / Equity
LUNG
LUNG
SFST
SFST
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
SFST
SFST
Operating Cash FlowLast quarter
$30.5M
Free Cash FlowOCF − Capex
$29.9M
FCF MarginFCF / Revenue
93.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$62.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
SFST
SFST
Q1 26
Q4 25
$-7.1M
$30.5M
Q3 25
$-8.2M
$14.5M
Q2 25
$-3.9M
$10.5M
Q1 25
$-13.2M
$7.6M
Q4 24
$-6.7M
$25.6M
Q3 24
$-7.2M
$26.3M
Q2 24
$-5.8M
$4.0M
Free Cash Flow
LUNG
LUNG
SFST
SFST
Q1 26
Q4 25
$-7.1M
$29.9M
Q3 25
$-8.3M
$14.4M
Q2 25
$-4.0M
$10.4M
Q1 25
$-13.5M
$7.4M
Q4 24
$-6.8M
$24.8M
Q3 24
$-7.7M
$26.1M
Q2 24
$-6.2M
$3.9M
FCF Margin
LUNG
LUNG
SFST
SFST
Q1 26
Q4 25
-31.4%
93.8%
Q3 25
-38.4%
46.3%
Q2 25
-16.6%
36.3%
Q1 25
-60.0%
28.1%
Q4 24
-28.8%
98.2%
Q3 24
-37.6%
110.0%
Q2 24
-30.0%
16.8%
Capex Intensity
LUNG
LUNG
SFST
SFST
Q1 26
Q4 25
0.1%
1.8%
Q3 25
0.4%
0.3%
Q2 25
0.2%
0.3%
Q1 25
1.3%
0.5%
Q4 24
0.5%
3.1%
Q3 24
2.0%
0.8%
Q2 24
2.3%
0.4%
Cash Conversion
LUNG
LUNG
SFST
SFST
Q1 26
Q4 25
Q3 25
1.67×
Q2 25
1.59×
Q1 25
1.44×
Q4 24
Q3 24
6.01×
Q2 24
1.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons